Amgen's Ven Biogram

An open industry secret is now official: Kurt von Emster's venBio had a first close of $75 million on its novel approach to a strategic venture fund, which will rely on a handful of major pharmas and biotechs as LPs.

Previously, von Emster founded and managed the MPM BioEquities fund at MPM Capital and prior to that was the founder and portfolio manager of the Franklin Biotechnology Discovery Fund at Franklin Templeton...